Market Closed -
Hong Kong S.E.
01:38:07 05/07/2024 pm IST
|
5-day change
|
1st Jan Change
|
88.6
HKD
|
+2.84%
|
|
+2.78%
|
-19.53%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
10,134
|
23,494
|
27,843
|
22,843
|
18,862
|
15,558
|
-
|
-
|
Enterprise Value (EV)
1 |
9,392
|
19,361
|
24,097
|
19,511
|
16,564
|
13,955
|
14,553
|
14,180
|
P/E ratio
|
-10.5
x
|
-13.5
x
|
-17.8
x
|
-11.3
x
|
-21.3
x
|
-16.3
x
|
-40.6
x
|
80.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
23.7
x
|
76.1
x
|
23.7
x
|
16.1
x
|
7.67
x
|
4.88
x
|
3.87
x
|
3.09
x
|
EV / Revenue
|
21.9
x
|
62.7
x
|
20.5
x
|
13.8
x
|
6.74
x
|
4.38
x
|
3.62
x
|
2.82
x
|
EV / EBITDA
|
-9.98
x
|
-11.9
x
|
-17.3
x
|
-11.3
x
|
-14.8
x
|
-17.8
x
|
-50.7
x
|
37.1
x
|
EV / FCF
|
-11.2
x
|
-13.8
x
|
-15.4
x
|
-10.7
x
|
-9.63
x
|
-17.7
x
|
-35.2
x
|
40
x
|
FCF Yield
|
-8.94%
|
-7.24%
|
-6.48%
|
-9.34%
|
-10.4%
|
-5.63%
|
-2.84%
|
2.5%
|
Price to Book
|
11.2
x
|
5.57
x
|
4.03
x
|
5.17
x
|
5.32
x
|
5.45
x
|
5.81
x
|
4.58
x
|
Nbr of stocks (in thousands)
|
61,136
|
90,924
|
1,02,770
|
1,03,859
|
1,04,578
|
1,05,810
|
-
|
-
|
Reference price
2 |
165.8
|
258.4
|
270.9
|
219.9
|
180.4
|
147.0
|
147.0
|
147.0
|
Announcement Date
|
02/03/20
|
25/02/21
|
25/02/22
|
27/02/23
|
26/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
428.2
|
308.9
|
1,176
|
1,416
|
2,459
|
3,186
|
4,022
|
5,031
|
EBITDA
1 |
-941.3
|
-1,626
|
-1,392
|
-1,723
|
-1,120
|
-782.1
|
-287
|
382.3
|
EBIT
1 |
-959.9
|
-1,658
|
-1,439
|
-1,790
|
-1,208
|
-940.6
|
-439
|
240.1
|
Operating Margin
|
-224.16%
|
-536.69%
|
-122.31%
|
-126.4%
|
-49.12%
|
-29.52%
|
-10.92%
|
4.77%
|
Earnings before Tax (EBT)
1 |
-943.6
|
-1,618
|
-1,439
|
-1,961
|
-825.8
|
-846.4
|
-367
|
296.7
|
Net income
1 |
-948.6
|
-1,597
|
-1,413
|
-2,004
|
-881.7
|
-859.3
|
-345.6
|
222.8
|
Net margin
|
-221.53%
|
-517.01%
|
-120.15%
|
-141.52%
|
-35.86%
|
-26.97%
|
-8.59%
|
4.43%
|
EPS
2 |
-15.80
|
-19.13
|
-15.23
|
-19.43
|
-8.450
|
-9.019
|
-3.625
|
1.826
|
Free Cash Flow
1 |
-839.9
|
-1,401
|
-1,562
|
-1,822
|
-1,719
|
-786.3
|
-413.7
|
354.7
|
FCF margin
|
-196.14%
|
-453.57%
|
-132.76%
|
-128.68%
|
-69.93%
|
-24.68%
|
-10.29%
|
7.05%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
92.77%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
159.22%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/03/20
|
25/02/21
|
25/02/22
|
27/02/23
|
26/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
214
|
420.4
|
306.6
|
341.6
|
387.6
|
380.1
|
606.4
|
447.8
|
595.3
|
1,043
|
781.3
|
634.4
|
751.7
|
793.9
|
827.6
|
885.9
|
806.6
|
973.1
|
EBITDA
1 |
-558.6
|
-
|
-426.7
|
-423.9
|
-422.2
|
-450.6
|
-
|
-351.2
|
-
|
-
|
-112.5
|
-565.3
|
-236.1
|
-293.1
|
-326.7
|
-185.5
|
-311.9
|
-111.1
|
EBIT
1 |
-571.7
|
-
|
-443.3
|
-439.4
|
-438.4
|
-468.6
|
-907
|
-371.3
|
-318.7
|
-690
|
-134
|
-589.1
|
-261.3
|
-279.2
|
-277.6
|
-210
|
-272.6
|
-133.6
|
Operating Margin
|
-267.19%
|
-
|
-144.57%
|
-128.64%
|
-113.09%
|
-123.29%
|
-149.56%
|
-82.91%
|
-53.54%
|
-66.15%
|
-17.15%
|
-92.86%
|
-34.77%
|
-35.17%
|
-33.54%
|
-23.7%
|
-33.79%
|
-13.73%
|
Earnings before Tax (EBT)
1 |
-586.8
|
-
|
-421.2
|
-557.6
|
-551.2
|
-431
|
-982.2
|
-336.9
|
-367.5
|
-704.4
|
229.3
|
-350.8
|
-243.4
|
-258.7
|
-237.6
|
-225.7
|
-185.1
|
-107.9
|
Net income
1 |
-585.7
|
-999.5
|
-434.3
|
-571.4
|
-557.6
|
-445.3
|
-998.1
|
-348.4
|
-381.1
|
-729.6
|
215.4
|
-367.6
|
-251.2
|
-255.8
|
-234.8
|
-222.1
|
-185.1
|
-107.9
|
Net margin
|
-273.7%
|
-237.74%
|
-141.63%
|
-167.3%
|
-143.84%
|
-117.16%
|
-164.59%
|
-77.81%
|
-64.03%
|
-69.94%
|
27.57%
|
-57.94%
|
-33.41%
|
-32.22%
|
-28.38%
|
-25.07%
|
-22.95%
|
-11.09%
|
EPS
2 |
-6.160
|
-
|
-4.240
|
-5.560
|
-5.390
|
-4.290
|
-
|
-3.340
|
-3.640
|
-
|
2.010
|
-3.480
|
-2.410
|
-2.453
|
-2.248
|
-2.121
|
-1.810
|
-1.050
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/02/22
|
25/02/22
|
05/05/22
|
04/08/22
|
09/11/22
|
27/02/23
|
27/02/23
|
04/05/23
|
02/08/23
|
02/08/23
|
09/11/23
|
26/02/24
|
08/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
742
|
4,132
|
3,746
|
3,332
|
2,297
|
1,603
|
1,006
|
1,379
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-840
|
-1,401
|
-1,562
|
-1,822
|
-1,719
|
-786
|
-414
|
355
|
ROE (net income / shareholders' equity)
|
-70.2%
|
-66.1%
|
-28%
|
-38.1%
|
-22.3%
|
-26.2%
|
-11.4%
|
11.7%
|
ROA (Net income/ Total Assets)
|
-49.1%
|
-44.3%
|
-19.8%
|
-26.9%
|
-14.5%
|
-17.3%
|
-8.24%
|
6.1%
|
Assets
1 |
1,931
|
3,607
|
7,123
|
7,457
|
6,093
|
4,958
|
4,194
|
3,653
|
Book Value Per Share
2 |
14.80
|
46.40
|
67.30
|
42.50
|
33.90
|
27.00
|
25.30
|
32.10
|
Cash Flow per Share
2 |
-12.50
|
-15.40
|
-14.00
|
-14.50
|
-11.10
|
-5.310
|
-1.900
|
5.280
|
Capex
1 |
89.6
|
118
|
263
|
325
|
562
|
277
|
250
|
273
|
Capex / Sales
|
20.93%
|
38.04%
|
22.35%
|
22.98%
|
22.85%
|
8.69%
|
6.23%
|
5.43%
|
Announcement Date
|
02/03/20
|
25/02/21
|
25/02/22
|
27/02/23
|
26/02/24
|
-
|
-
|
-
|
Average target price
267
USD Spread / Average Target +81.59% Consensus |
1st Jan change
|
Capi.
|
---|
| +16.61% | 122B | | +17.75% | 112B | | +17.23% | 25.91B | | -24.11% | 19.33B | | -18.56% | 16.17B | | -47.75% | 14.65B | | +57.35% | 14.34B | | +5.62% | 14B | | +125.88% | 11.29B |
Bio Therapeutic Drugs
|